SCHEMBL3165072

SCHEMBL3165072

Cc1ccc(-n2nc([Si](C)(C)C)cc2NC(=O)OCC(Cl)(Cl)Cl)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK8 P49336 2/20 0.45
MAPK14 Q16539 8/20 0.44
MAPK13 O15264 5/20 0.44
MAPK12 P53778 4/20 0.44
MAPK11 Q15759 4/20 0.44
CCNC P24863 1/20 0.42
SMN1; SMN2 Q16637 4/20 0.40
LMNA P02545 3/20 0.40
NPSR1 Q6W5P4 2/20 0.40
ALDH1A1 P00352 2/20 0.40
HTT P42858 2/20 0.40
MEN1 O00255 1/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 1/20 0.40
KMT2A Q03164 1/20 0.40
SRC P12931 2/20 0.40
SYK P43405 2/20 0.40
GSK3A P49840 2/20 0.40
MAPK9 P45984 1/20 0.39
PTK2 Q05397 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL378881 0.85 CDK8 (0.63) CDK8MAPK14MAPK13MAPK12MAPK11
SCHEMBL3176730 0.83 CDK8 (0.46) CDK8MAPK14MAPK13MAPK12MAPK11
SCHEMBL14539234 0.83 CDK8 (0.43) CDK8MAPK14MAPK13MAPK12MAPK11
SCHEMBL3390231 0.82 CDK8 (0.50) CDK8MAPK14MAPK13MAPK12MAPK11
SCHEMBL3777160 0.82 MAPK14 (0.57) CDK8MAPK14MAPK13MAPK12MAPK11
SCHEMBL3174427 0.82 CDK8 (0.53) CDK8MAPK14MAPK13MAPK12MAPK11
SCHEMBL3185420 0.82 KCNJ6 (0.56) CDK8
SCHEMBL3174490 0.82 CDK8 (0.53) CDK8MAPK14MAPK13MAPK12MAPK11
SCHEMBL3181221 0.81 CDK8 (0.55) CDK8MAPK14MAPK13MAPK12MAPK11
SCHEMBL15006795 0.81 SMN1; SMN2 (0.41) CDK8MAPK14CCNCSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1943243-B1 KINASE INHIBITORS LILLY CO ELI (US) 2010-12-29 EP disclosed
US-7652015-B2 Suppression cytokines , tumor necrosis factor ELI LILLY AND COMPANY (US) 2010-01-26 US disclosed
US-20080269244-A1 Kinase Inhibitors ELI LILLY AND COMPANY 2008-10-30 US disclosed
EP-1943243-A1 KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2008-07-16 EP disclosed
WO-2007053394-A1 KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2007-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269244-A1 Kinase Inhibitors MAP3K1, MAP3K20, MAP3K19 CDK8 338/4885MAPK14 58/4885MAPK13 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.